Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsTranslating TrialsCase-Based Peer PerspectivesPodcastsVideosShorts
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Sarah Low, RN, MSN, OCN, CMSRN

Advertisement

Articles by Sarah Low, RN, MSN, OCN, CMSRN

Sarah Low

Low and Maldonado on Leveraging Wearable Devices to Improve Inpatient Ambulation

BySarah Low, RN, MSN, OCN, CMSRN,Claudia Maldonado-Howell, RN, MSN, FNP, BS
May 8th 2023

Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Oncology Nursing News

    1

    FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer

    2

    Prostate Cancer Care: ADT Management and APP Guidance

    3

    Oncology Experts Discuss On-Body Subcutaneous Isatuximab in Multiple Myeloma

    4

    Gynecologic Cancer Awareness: Dr. Teplinsky Discusses Nursing Roles

    5

    FDA Approves sNDA for Taletrectinib in ROS1+ NSCLC

    • About Us
    • Editorial Board
    • Contact Us
    • CancerNetwork.com
    • CureToday.com
    • OncLive.com
    • TargetedOnc.com
    • Advertise
    • Privacy
    • Terms & Conditions
    • Do Not Sell My Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us